Clinical Trial Update: A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy [Phase 2]

View source ↗

Summary

A phase II trial assessing gefitinib (ZD1839) in combination with tamoxifen for epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer that is r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Tamoxifen (tamoxifen)
• gefitinib (ZD1839) (gefitinib)

Snippet

Sponsor: AGO Study Group | Conditions: Ovarian Cancer, Cancer of the Fallopian Tube | Phase 2 | Status: COMPLETED